Literature DB >> 10701768

Immunohistochemical analysis of estrogen receptors in feline mammary gland benign and malignant lesions: comparison with biochemical assay.

J M de las Mulas1, M van Niel, Y Millán, M A Blankenstein, F van Mil, W Misdorp.   

Abstract

Estrogen receptors (ER) were determined by both the biochemical dextran-coated charcoal (DCC-ER) and the immunohistochemical Avidin biotin-peroxidase complex (IHC-ER) methods in proliferative mammary lesions collected from 37 cats: 20 malignant tumors without metastasis at first presentation, seven malignant tumors with lung and/or lymph node metastases and 10 benign tumors and dysplasias. Total number of samples analyzed by both methods was 44. The DCC-ER method was applied to frozen tissue samples and the IHC-ER method was applied to neutral buffered formalin-fixed, paraffin wax-embedded tissue samples by using the NCL-6F11 monoclonal antibody. Biochemically, 21 (47.7%) cases had equal or more than 5 fmol/mg of protein (standard positivity threshold). Immunohistochemically, 11 (25%) cases were scored positive, the percentage of positive nuclei being statistically linked to the intensity of immunostaining. Normal mammary gland tissue (13 cases) and/or dysplastic areas (5 cases) found in the surroundings of the main lesion were IHC-ER positive in 76.9% and 40% of the cases, respectively. Concordance between DCC-ER and IHC-DCC was 72.7% and the results of the DCC and the IHC-ER methods were significantly correlated (P < 0.05) by the chi2 test. Specificity (true negatives) and sensitivity (true positives) of the ICH-ER method were 95.6% and 47.6%, respectively. One out of eleven DCC-ER positive and IHC-ER negative discordant cases (9.09%) was a DCC-ER false positive, because the surrounding normal mammary gland tissue was IHC-ER positive. The remaining 10 cases had ER content values equal or lower than 23 fmol/mg of protein, a figure that could represent the sensitivity threshold of the immunohistochemical method employed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10701768     DOI: 10.1016/s0739-7240(99)00067-3

Source DB:  PubMed          Journal:  Domest Anim Endocrinol        ISSN: 0739-7240            Impact factor:   2.290


  9 in total

1.  St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study.

Authors:  M Soares; J Correia; M C Peleteiro; F Ferreira
Journal:  Tumour Biol       Date:  2015-10-20

2.  Mammary Fibroadenoma in Cats: A Matter of Classification.

Authors:  Filippo Torrigiani; Valentina Moccia; Barbara Brunetti; Francesca Millanta; Guillermo Valdivia; Laura Peña; Laura Cavicchioli; Valentina Zappulli
Journal:  Vet Sci       Date:  2022-05-26

3.  fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions.

Authors:  Maria Soares; Assunção N Correia; Mariana R Batista; Jorge Correia; Fernando Ferreira
Journal:  Animals (Basel)       Date:  2022-06-21       Impact factor: 3.231

4.  Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions.

Authors:  Giovanni P Burrai; Sulma I Mohammed; Margaret A Miller; Vincenzo Marras; Salvatore Pirino; Maria F Addis; Sergio Uzzau; Elisabetta Antuofermo
Journal:  BMC Cancer       Date:  2010-04-22       Impact factor: 4.430

5.  CXCR4 expression in feline mammary carcinoma cells: evidence of a proliferative role for the SDF-1/CXCR4 axis.

Authors:  Angelo Ferrari; Claudio Petterino; Alessandra Ratto; Chiara Campanella; Roberto Wurth; Stefano Thellung; Guendalina Vito; Federica Barbieri; Tullio Florio
Journal:  BMC Vet Res       Date:  2012-03-14       Impact factor: 2.741

6.  Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.

Authors:  David A Wiese; Tuddow Thaiwong; Vilma Yuzbasiyan-Gurkan; Matti Kiupel
Journal:  BMC Cancer       Date:  2013-09-03       Impact factor: 4.430

7.  Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.

Authors:  Lorella Maniscalco; Yolanda Millán; Selina Iussich; Mauro Denina; Raquel Sánchez-Céspedes; Francesca Gattino; Bartolomeo Biolatti; Nobuo Sasaki; Takayuki Nakagawa; Maria Flavia Di Renzo; Juana Martín de Las Mulas; Raffaella De Maria
Journal:  BMC Vet Res       Date:  2013-04-15       Impact factor: 2.741

8.  Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study.

Authors:  Javier Ordás; Yolanda Millán; Rafaela Dios; Carlos Reymundo; Juana Martín de Las Mulas
Journal:  BMC Cancer       Date:  2007-09-20       Impact factor: 4.430

9.  An immunohistochemical study on the expression of sex steroid receptors, Ki-67 and cytokeratins 7 and 20 in feline endometrial adenocarcinomas.

Authors:  Ana Laura Saraiva; Rita Payan-Carreira; Fátima Gärtner; Marta R Fortuna da Cunha; Alexandra Rêma; Fátima Faria; Lígia M Lourenço; Maria Dos Anjos Pires
Journal:  BMC Vet Res       Date:  2015-08-14       Impact factor: 2.741

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.